Medscape reports that two new studies discussed at ASCO 2017 in Chicago are optimistic about treatments for mesothelioma.
“Immune checkpoint inhibitors are likely to change our standard of care in malignant pleural mesothelioma,” said Anne Tsao, MD, a medical oncologist from MD Anderson Cancer Center in Houston, Texas, who spoke here at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting.
Furthermore, antiangiogenic agents, which have a budding role in the treatment of mesothelioma, may eventually be used by clinicians in combination with immunotherapy, she said.
In short, welcome change is coming to this notoriously difficult-to-treat form of lung cancer that currently has only one proven first-line regimen, and none for patients who experience disease relapse or progression.
Get the whole story at www.medscape.com